Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2017 Summary P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein that in humans is encoded by the P2RX3 gene. It belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel and may transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes. P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3 and 3 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Respiratory, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Neuropathic Pain, Chronic Cough, Chronic Pain, Hypertension, Visceral Pain, Abdominal Pain, Alzheimer's Disease, Endometriosis, Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Insomnia, Interstitial Cystitis (Painful Bladder Syndrome), Memory Impairment, Migraine, Ocular Hypertension, Open-Angle Glaucoma, Osteoarthritis Pain, Pain, Resistant Hypertension and Respiratory Tract Infections. The latest report P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2017, outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3) - The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects - The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage P2X Purinoceptor 3 (P2RX3) - Overview P2X Purinoceptor 3 (P2RX3) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development Asana BioSciences LLC Bayer AG BELLUS Health Inc Integral Molecular Inc Merck & Co Inc Neurim Pharmaceuticals Ltd Pfizer Inc P2X Purinoceptor 3 (P2RX3) - Drug Profiles AF-130 - Drug Profile Product Description Mechanism Of Action R&D Progress ASN-009 - Drug Profile Product Description Mechanism Of Action R&D Progress BLU-5937 - Drug Profile Product Description Mechanism Of Action R&D Progress Drug to Antagonize P2X3 for Endometriosis - Drug Profile Product Description Mechanism Of Action R&D Progress gefapixant - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile Product Description Mechanism Of Action R&D Progress OSX-300 - Drug Profile Product Description Mechanism Of Action R&D Progress OSX-300 Backups - Drug Profile Product Description Mechanism Of Action R&D Progress piromelatine - Drug Profile Product Description Mechanism Of Action R&D Progress P2X Purinoceptor 3 (P2RX3) - Dormant Products P2X Purinoceptor 3 (P2RX3) - Discontinued Products P2X Purinoceptor 3 (P2RX3) - Product Development Milestones Featured News & Press Releases May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease Sep 05, 2016: Hypertension: releasing the pressure at its source May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indication, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Asana BioSciences LLC, H2 2017 Pipeline by Bayer AG, H2 2017 Pipeline by BELLUS Health Inc, H2 2017 Pipeline by Integral Molecular Inc, H2 2017 Pipeline by Merck & Co Inc, H2 2017 Pipeline by Neurim Pharmaceuticals Ltd, H2 2017 Pipeline by Pfizer Inc, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
